{"product_id":"abcam-ab205921","title":"Abcam, ab205921, Anti-PD-L1 antibody [28-8]","description":"\u003cp\u003eSize: 20µL \/ 50µL\u003cbr\u003e\nAnti-PD-L1 antibody [28-8] (ab205921) is a rabbit monoclonal antibody detecting PD-L1 in  Western Blot, Flow Cytometry, IHC-P, IHC-Fr, ICC\/IF, mIHC . Suitable for  Human . - KO validated for confirmed specificity - Multiplex IHC validated on the Leica BOND® MAX using Opal reagents - Biophysical QC for unrivalled batch-batch consistency - Over 470 publications\u003cbr\u003e\nKey facts\u003cbr\u003e\nHost species:Rabbit,\u003cbr\u003e\nClonality:Monoclonal,\u003cbr\u003e\nClone number:28-8,\u003cbr\u003e\nIsotype:IgG,\u003cbr\u003e\nCarrier free:No,\u003cbr\u003e\nReacts with:Human,\u003cbr\u003e\nApplications:ICC\/IF, Flow Cyt, WB, mIHC, IHC-P, IHC-FrSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,\u003cbr\u003e\nImmunogen:The exact immunogen used to generate this antibody is proprietary information.\u003c\/p\u003e\n\n\u003cp\u003eProduct details:\u003cbr\u003e\nAnti-PD-L1 antibody [28-8] (ab205921) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in Flow Cyt, ICC\/IF, IHC-Fr, IHC-P, WB, mIHC in human samples.\u003cbr\u003e\nAnti-PD-L1 antibody [28-8] (ab205921) has been cited over 476 times in peer reviewed journals and is trusted by the scientific community.\u003cbr\u003e\nAbcam's high quality manufacturing and validation processes ensure Anti-PD-L1 antibody [28-8] (ab205921) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility.\u003cbr\u003e\nThe specificity of Anti-PD-L1 antibody [28-8] (ab205921) has been confirmed by testing in knockout samples.\u003cbr\u003e\nAnti-PD-L1 antibody [28-8] (ab205921) has 13 independent reviews from customers.\u003cbr\u003e\nAnti-PD-L1 antibody [28-8] (ab205921) specifically detects PD-L1 (UniProt ID: Q9NZQ7; Molecular weight: 31kDa) and is sold in a convenient trial size to enable initial testing (20 µL) and larger sizes for subsequent scaling up experiments (50 µL).\u003cbr\u003e\nConjugation-ready, carrier free format available for antibody clone 28-8 -\u003cbr\u003e\nab228413\u003cbr\u003e\nAntibody clone 28-8 is also available pre-conjugated to a variety of labels for your convenience - HRP, PE, Alexa Fluor® 555, Alexa Fluor® 568, Alexa Fluor® 594, FITC (\u003cbr\u003e\nab209961\u003cbr\u003e\nab209962\u003cbr\u003e\nab213358\u003cbr\u003e\nab213359\u003cbr\u003e\nab213360\u003cbr\u003e\nab224027\u003cbr\u003e\nPD-L1 (Programmed Death-Ligand 1) is a protein that plays a significant role in oncology, particularly in the immune response to cancer. It is expressed on the surface of cancer cells and interacts with the PD-1 receptor on T-cells, effectively inhibiting the immune system's ability to attack the tumor. This interaction is a key target for immunotherapy drugs, such as checkpoint inhibitors, which block the PD-1\/PD-L1 pathway, allowing the immune system to recognize and destroy cancer cells.\u003cbr\u003e\nFURTHER INFORMATION ON POSITIVE CONTROLS (\u003cbr\u003e\nChinese version\u003cbr\u003e\nTissue:\u003cbr\u003e\n- Tonsil - with hyperreactive changes. Screening of hyper-reactive tonsils is recommended to find tonsil with the highest expression of PD-L1 in crypt epithelium, macrophages homing the germinal centers and interfollicular mononuclear leukocytes.\u003cbr\u003e\n- Tumor tissues - prescreened for positive tumor and inflammatory infiltrates. PD-L1 expression varies by tumor type so screening is recommended to find positive and negative tumor controls.\u003cbr\u003e\n- The following publication is useful for finding suitable tumor types for PD-L1 expression:\u003cbr\u003e\nhttp:\/\/www.immunotherapyofcancer.org\/content\/1\/S1\/P53\u003cbr\u003e\n- Note: Look for specimens with high numbers of inflammatory macrophages and mononuclear leukocytes.\u003cbr\u003e\nCell Lines:\u003cbr\u003e\n- Positive controls: B-CPAP (high), ES-2 (medium), HCC70 (low).\u003cbr\u003e\nPrimary antibody negative control:\u003cbr\u003e\nRecombinant Rabbit IgG isotype control antibody,\u003cbr\u003e\nab172730\u003cbr\u003e\nRecombinant protein positive control:\u003cbr\u003e\nRecombinant human PD-L1 protein,\u003cbr\u003e\nab167713\u003cbr\u003e\nImmunohistochemistry usage:\u003cbr\u003e\nFor IHC usage on FFPE tissues, we recommend using PD-L1 IHC panel\u003cbr\u003e\nab236676\u003cbr\u003e\n, which contains PD-L1 antibody clone 28-8 (ab205921), HIER antigen retrieval reagent (\u003cbr\u003e\nab208572\u003cbr\u003e\n) and IHC detection kit HRP\/DAB (\u003cbr\u003e\nab209101\u003cbr\u003e\nWestern blot usage:\u003cbr\u003e\nFor clone 28-8, it is recommended to use Odyssey system. This system has the advantages of a wider dynamic range and less background than chemiluminescence.\u003cbr\u003e\nThis PD-L1 antibody [28-8] has been used as detector antibody in Human PD-L1 SimpleStep ELISA\u003cbr\u003e\nkit: ab214565 and\u003cbr\u003e\nab277712\u003cbr\u003e\nTo support you in your biomarker discovery and validation studies, we offer a\u003cbr\u003e\ncomprehensive suite of solutions\u003cbr\u003e\nincluding high quality, validated recombinant antibodies and assay kits.\u003cbr\u003e\nPatented technology\u003cbr\u003e\nOur RabMAb\u003cbr\u003e\ntechnology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to\u003cbr\u003e\nRabMAb® patents\u003cbr\u003e\nWhat are the advantages of a recombinant monoclonal antibody?\u003cbr\u003e\nThis product is a recombinant monoclonal antibody, which offers several advantages including:\u003cbr\u003e\n- High batch-to-batch consistency and reproducibility\u003cbr\u003e\n- Improved sensitivity and specificity\u003cbr\u003e\n- Long-term security of supply\u003cbr\u003e\n- Animal-free batch production\u003cbr\u003e\nFor more information, read more on\u003cbr\u003e\nrecombinant antibodies\u003c\/p\u003e\n\n\u003cp\u003eProperties and Storage Information:\u003cbr\u003e\nForm-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Preservative: 0.01% Sodium azideConstituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze \/ thaw cycle\u003c\/p\u003e\n\n\u003cp\u003eSupplementary Information:\u003cbr\u003e\nThis supplementary information is collated from multiple sources and compiled automatically.\u003cbr\u003e\nPD-L1 also known as programmed death-ligand 1 or CD274 plays an important role in the immune system. It is a protein expressed on antigen-presenting cells and some tumor cells helping them interact with T-cells. The molecular weight of PD-L1 is approximately 33 kDa. PD-L1 expression can occur in various tissues and is often upregulated in tumor microenvironments. This increased expression helps tumors evade the immune response.\u003cbr\u003e\nBiological function summary\u003cbr\u003e\nPD-L1 modulates the immune response by interacting with its receptor PD-1 on T-cells and other immune cells leading to immune suppression. It is part of the PD-1\/PD-L1 complex an important regulator of T-cell activity and immune tolerance. The binding of PD-L1 to PD-1 inhibits T-cell proliferation and cytokine production reducing the ability of the immune system to attack cancer cells.\u003cbr\u003e\nPathways\u003cbr\u003e\nPD-L1 is involved in the immune checkpoint pathway and the cancer immunity cycle. Its interaction with PD-1 influences important signaling cascades within these pathways affecting the immune system's capacity to target tumor cells effectively. Another protein important in this context is CTLA-4 another immune checkpoint regulator which along with PD-1 modulates immune system activity against cancer.\u003cbr\u003e\nPD-L1 has strong connections to cancer and autoimmune diseases. Many cancers including melanoma and non-small cell lung cancer exploit PD-L1 to protect themselves from the immune system. Increased PD-L1 expression can also impact autoimmune disorders where the immune system reacts against healthy body tissues. This interaction further involves PD-1 and CTLA-4 illustrating their shared roles in these disease contexts.\u003c\/p\u003e","brand":"Abcam","offers":[{"title":"Default Title","offer_id":46844030451881,"sku":"ab205921","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/es\/products\/abcam-ab205921","provider":"Iright","version":"1.0","type":"link"}